Clinical Data Sees Positive Results from Pivotal Depression Drug Trial

Apocalypse Suicide Page
Good Mood
Living with Depression
Mental Health Recovery
NIMH
SHOCKED! ECT

HealthyPlace.com Radio
Depression Support Groups

Books on Depression
Conference Transcripts
Depression Videos
Diaries - Journals
Disorders Definitions
Mental Health News
Online Depression Tests
Psychiatric Medications
Resources
Site Map

Email
ICQ
Instant Messenger

Visit and Post

Abuse
ADD/ADHD
Addictions
Anxiety-Panic
Bipolar
Eating Disorders
Personality Disorders
Self-Injury

send this page to a friend

Clinical Data Sees Positive Results from Pivotal Depression Drug Trial

(September 6, 2007) Clinical Data has announced positive results from a Phase III study of its investigative compound Vilazodone for the treatment of depression. According to the company, the primary and supportive secondary efficacy endpoints were met in the study.

The randomized, double-blind, placebo-controlled study of 410 adult patients with major depressive disorder achieved the primary endpoint of mean change from baseline in the Montgomery-Asberg Depression Rating Scale total score compared to the placebo.

Vilazodone also met a key secondary endpoint during the study, as measured by mean change from baseline on the Hamilton Depression Rating Scale. These two rating scales are the most common psychometric measures of response to antidepressants.

The study also identified candidate biomarkers for a potential companion test for predicting the response to Vilazodone. According to Clinical Data, Vilazodone is the only compound that combines two mechanisms used as first and second line treatments for mood disorders.

Drew Fromkin, president and CEO of Clinical Data, said: "This positive result with Vilazodone to date, coupled with our demonstrated ability to bring proprietary, pharmacogenetic tests to market, signals a new era for Clinical Data."

Carol Reed, Clinical Data's chief medical officer, added: "The implications for patients suffering from depression are exciting. We look forward to meeting with the FDA to discuss our remaining clinical trials program in support of our NDA filing on this important new therapeutic candidate and on a potential genetically based companion diagnostic."

By: Clare Watson
Source: Pharmaceutical Business Review

Last updated: 09/07

Clinical Data Sees Positive Results from Pivotal Depression Drug Trial

Related Stories